MIRA Completes Phase 1 Trial of Ketamir-2 Therapy

MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an update.

MIRA Pharmaceuticals, Inc. announced it has completed dosing in a Phase 1 clinical trial of its selective oral NMDA receptor modulator Ketamir-2 in 56 healthy volunteers at Hadassah Medical Center in Jerusalem. The randomized, double-blind, placebo-controlled study across single and multiple ascending dose cohorts reported no serious adverse events, dose-limiting toxicities, or ketamine-like dissociative or psychotomimetic effects, and final pharmacokinetic and safety analyses are underway.

The company plans to submit a Phase 2a proof-of-concept trial to the U.S. Food and Drug Administration in the first half of 2026 to evaluate Ketamir-2 in patients with moderate to severe chemotherapy-induced peripheral neuropathy. With CIPN lacking any FDA-approved, specifically indicated treatments and current management relying on off-label agents or intravenous ketamine, the advancement of Ketamir-2 positions MIRA to potentially address a significant unmet need in neuropathic pain and to present Phase 1 data at an upcoming scientific meeting.

The most recent analyst rating on (MIRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel oral neuromodulators, including its proprietary selective NMDA receptor modulator Ketamir-2. The company focuses on addressing unmet medical needs in neuropathic pain, with an initial market focus on chemotherapy-induced peripheral neuropathy where no FDA-approved therapies currently exist.

Average Trading Volume: 179,261

Technical Sentiment Signal: Sell

Current Market Cap: $54.02M

For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.